Susanna V. Ulahannan

Author

Also Known As

A Itani, S Ulahannan, S. Ulahannan, S.V. Ulahannan, SV Ulahannan, Susanna Ulahannan, Susanna V Ulahannan, Susanna V. Ulahannan, Susanna Varkey Ulahannan

258

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

Sarah Cannon Tennessee Oncology University of Oklahoma Health Sciences Center The University of Texas MD Anderson Cancer Center OU Health Stephenson Cancer Center

About

Susanna V. Ulahannan is an author at Sarah Cannon specializing in medicine, cancer therapeutics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	21	1.6K
2	Immunology	10	10	206
3	Health Sciences	4	4	415
4	Hepatology	4	4	1.2K
5	Cell Biology	1	1	71

Susanna V. Ulahannan

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma Austin G. Duffy, Susanna V. Ulahannan, Oxana Makorova-Rusher, Journal of Hepatology HepatologyMedicinePathologyLiver CancerCancer Treatment	2016	800
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial Josep M. Llovet, Masatoshi Kudo, Philippe Merle, The Lancet Oncology OncologyHepatologyMedicineClinical TrialsPembrolizumab Versus Lenvatinib	2023	364
Population attributable fractions of risk factors for hepatocellular carcinoma in the United States Oxana V. Makarova‐Rusher, Sean F. Altekruse, Tim S. McNeel, Cancer	2016	321
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial Jason J. Luke, Manish R. Patel, George R. Blumenschein, Nature Medicine	2023	111
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial Jayesh Desai, Guzmán Alonso, Se Hyun Kim, Nature Medicine	2023	106
Earlier presentation and application of curative treatments in hepatocellular carcinoma Susanna V. Ulahannan, Austin G. Duffy, Timothy S. McNeel, Hepatology	2014	82
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma Austin G. Duffy, Chi Ma, Susanna V. Ulahannan, Clinical Cancer Research	2017	74
Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan‐refractory colorectal cancer Austin G. Duffy, Oxana V. Makarova‐Rusher, Susanna V. Ulahannan, International Journal of Cancer	2016	73
A12 The SHP2 Inhibitor RMC-4630 in Patients with KRAS-Mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical Trial Sai‐Hong Ignatius Ou, Marianna Koczywas, Susanna V. Ulahannan, Journal of Thoracic Oncology MedicinePathologyBronchial NeoplasmImmune Checkpoint InhibitorShp2 Inhibitor Rmc-4630	2020	71
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors Emerson A. Lim, Johanna C. Bendell, Gerald S. Falchook, Clinical Cancer Research	2022	67

Page 1